ReviewAustralian prescriber2025
Medicines used in the treatment of opioid dependence.
Review in Australian prescriber, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Medication transitions and predictors of illicit substance use during opioid agonist treatment: a three-year follow-up study.Addiction science & clinical practice · 2026Observational
- Experiences and Predictors of Real-Time Prescription Drug Monitoring Program Use Among Australian Community Pharmacists: A Nationwide Study.Drug and alcohol review · 2026Article
- Risks associated with sublingual buprenorphine prescribing, dispensing and administration.Australian prescriber · 2025Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid dependence is a chronic condition that can lead to significant harm if left untreated. People who experience opioid dependence and the treatments themselves are highly stigmatised. Person-centred trauma-informed services are critical to therapeutic engagement and effectiveness. Buprenorphine and methadone are highly effective, evidence-based medicines for opioid dependence. In recent years, long-acting injectable buprenorphine has emerged as a safe and effective treatment option, offering flexible weekly or monthly dosing. The long-term treatment of opioid dependence can be undertaken in primary care settings. General practitioner and nurse practitioner prescribing, and community pharmacist dispensing, are essential for ongoing care. Australian jurisdictions have differing regulations that guide the prescribing of medicines for opioid dependence. Health professionals should be familiar with their local jurisdiction's guidelines as well as the national guidelines. Drug and alcohol telephone services are available in each jurisdiction and can provide advice to health professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.